leadf
logo-loader
viewImmuPharma PLC

Immupharma PLC - 2020 AGM – ALL RESOLUTIONS PASSED

RNS Number : 3880Q
Immupharma PLC
18 June 2020
 

 

 

 

18 June 2020

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2020 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

 

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed, by way of a poll.

-Ends-

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGZZGMVGRNGGZM

Quick facts: ImmuPharma PLC

Follow
AIM:IMM

Price: 7.74

Market Cap: £19.37 m

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s CEO, Tim McCarthy, presents commercial strategy for lupus drug...

ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.  The study...

on 17/8/21

3 min read